Director at Candel Therapeutics (NASDAQ: CADL) gets 32,000 options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Candel Therapeutics director Nicoletta Loggia received a grant of stock options to buy 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036. Following this grant, she holds options covering 32,000 shares.

The award is subject to time-based vesting. The options vest and become exercisable on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders, with vesting stopping if she leaves the board unless the board decides otherwise.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Loggia Nicoletta

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 32,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 32,000 options Exercise price: $9.08 per share Underlying shares: 32,000 shares +2 more

5 metrics

Options granted 32,000 options Stock Option (Right to Buy) grant to director

Exercise price $9.08 per share Exercise price of stock option award

Underlying shares 32,000 shares Common Stock underlying the option

Expiration date June 23, 2036 Option expiration

Vesting date trigger June 23, 2027 or next annual meeting Earlier date determines vesting

Key Terms

Stock Option (Right to Buy), time-based vesting, Annual Meeting of Stockholders, Board of Directors

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

time-based vesting financial

"This option is subject to time-based vesting."

Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.

Annual Meeting of Stockholders financial

"the date of the next Annual Meeting of Stockholders of the Issuer"

Board of Directors financial

"resigns from the Board of Directors (the "Board") of the Issuer"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/24/2026 - 04:35 PM Accepted by SEC EDGAR 06/24/2026 - 04:34 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Loggia Nicoletta

(Last)

(First)

(Middle)

C/O CANDEL THERAPEUTICS, INC.

117 KENDRICK ST., SUITE 450

(Street)

NEEDHAM

MASSACHUSETTS

02494

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Candel Therapeutics, Inc. [ CADL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$9.08	06/23/2026		A		32,000		⁽¹⁾	06/23/2036	Common Stock	32,000	$0	32,000	D

Explanation of Responses:

1. This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.

	/s/ Charles Schoch, as Attorney-In-Fact for Nicoletta Loggia	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Candel Therapeutics (CADL) report for Nicoletta Loggia?

Candel Therapeutics reported that director Nicoletta Loggia received a grant of stock options for 32,000 shares of common stock. These options give her the right to buy shares at a fixed price as part of her director compensation.

How many Candel Therapeutics (CADL) stock options were granted to Nicoletta Loggia?

Nicoletta Loggia was granted stock options covering 32,000 shares of Candel Therapeutics common stock. This entire amount reflects a single award, and after the grant she holds options for 32,000 underlying shares according to the Form 4 disclosure.

What is the exercise price of Nicoletta Loggia’s Candel Therapeutics (CADL) stock options?

The exercise price of Nicoletta Loggia’s stock options is $9.08 per share. This means she can purchase Candel Therapeutics common stock at $9.08 once the options have vested and are exercisable under the award’s terms.

When do Nicoletta Loggia’s Candel Therapeutics (CADL) options vest?

The stock options vest on the earlier of June 23, 2027 or the date of Candel Therapeutics’ next Annual Meeting of Stockholders. Vesting stops if she resigns from the board or otherwise ceases to serve as a director, unless the board decides to continue vesting.

What is the expiration date of the Candel Therapeutics (CADL) options granted to Nicoletta Loggia?

The options granted to Nicoletta Loggia expire on June 23, 2036. After that expiration date, any unexercised portion of the award can no longer be used to purchase Candel Therapeutics common stock under this grant.

Does Nicoletta Loggia need to remain on Candel Therapeutics’ (CADL) board for her options to vest?

Yes, vesting is tied to her board service. All vesting stops if she resigns from the Candel Therapeutics board or otherwise ceases to serve as a director, unless the board determines that circumstances justify continuing the vesting schedule for this option.